Liqbiopsens | Reliable Novel Liquid Biopsy technology for early detection of colorectal cancer

Summary
The overall aim of LIQBIOPSENS project is the further development and validation in real settings of a novel diagnostic platform for the early and fast detection of ctDNA and their KRAS and BRAF mutations associated to colorectal cancer through blood samples. The main features of LIQBIOPSENS are: reliability (detection rates vary from 95–100 %), low-cost (40-50 € per sample analysis), sensitivity (in the zM range), multiplexing capabilities (analysis of 27 KRAS and BRAF mutations simultaneously), short analysis time (30-60 min.), user-friendly interface and flexibility. Solution proposed by the LIQBIOPSENS project relies on the multidisciplinary integration of different Key Enabled Technologies: microelectronics, microfluidics, nanomaterials and genomics. In particular, LIQBIOPSENS platform is based on the integration of two novel complementary technologies. On the one hand, the revolutionary DGL© technology property of DestiNA Genomics Ltd, capable of delivering faster, more error-free detection of nucleic acids and their mutations than current enzyme-based detection systems, making 'false positive' results a thing of the past. On the other hand, a novel high resolution acoustic wave microsensor technology property of AWSensors, that allows an accurate, inexpensive, label-free, direct and real time transduction method to quantitatively evaluate the results of the application of the above mentioned DGL© technique.
Unfold all
/
Fold all
More information & hyperlinks
Web resources: https://cordis.europa.eu/project/id/687785
Start date: 01-01-2016
End date: 31-12-2018
Total budget - Public funding: 2 702 268,75 Euro - 2 307 200,00 Euro
Cordis data

Original description

The overall aim of LIQBIOPSENS project is the further development and validation in real settings of a novel diagnostic platform for the early and fast detection of ctDNA and their KRAS and BRAF mutations associated to colorectal cancer through blood samples. The main features of LIQBIOPSENS are: reliability (detection rates vary from 95–100 %), low-cost (40-50 € per sample analysis), sensitivity (in the zM range), multiplexing capabilities (analysis of 27 KRAS and BRAF mutations simultaneously), short analysis time (30-60 min.), user-friendly interface and flexibility. Solution proposed by the LIQBIOPSENS project relies on the multidisciplinary integration of different Key Enabled Technologies: microelectronics, microfluidics, nanomaterials and genomics. In particular, LIQBIOPSENS platform is based on the integration of two novel complementary technologies. On the one hand, the revolutionary DGL© technology property of DestiNA Genomics Ltd, capable of delivering faster, more error-free detection of nucleic acids and their mutations than current enzyme-based detection systems, making 'false positive' results a thing of the past. On the other hand, a novel high resolution acoustic wave microsensor technology property of AWSensors, that allows an accurate, inexpensive, label-free, direct and real time transduction method to quantitatively evaluate the results of the application of the above mentioned DGL© technique.

Status

CLOSED

Call topic

ICT-28-2015

Update Date

27-10-2022
Images
No images available.
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
Horizon 2020
H2020-EU.2. INDUSTRIAL LEADERSHIP
H2020-EU.2.1. INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies
H2020-EU.2.1.1. INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT)
H2020-EU.2.1.1.0. INDUSTRIAL LEADERSHIP - ICT - Cross-cutting calls
H2020-ICT-2015
ICT-28-2015 Cross-cutting ICT KETs